SLC9A2 and neoplasm: Our preliminary experimental data demonstrated that highly metastatic tumor cells activate the STAT3 signaling pathway by downregulating SLC9A2, facilitating tumor cell migration and invasion, leading us to hypothesize that STAT3 signaling might also be involved in the angiogenic pathway.